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ABSTRACT
Objectives: To evaluate the relationship between bone
mineral density (BMD) and biomarkers of bone turnover
and inflammation in patients with ankylosing spondylitis
(AS) treated with infliximab.
Methods: Patients (n=279) were randomly assigned
(3:8) to receive placebo or 5 mg/kg infliximab every
6 weeks through week 96. At week 24, placebo-treated
patients crossed over to infliximab 5 mg/kg. Starting at
week 36, patients treated with infliximab received dose
escalations to 7.5 mg/kg. Hip and spine BMD were
measured (baseline, week 24, week 102) using dual-
energy x-ray absorptiometry. Sera were analysed (base-
line, week 24, week 102) for levels of bone alkaline
phosphatase (BAP), osteocalcin, C-terminal cross-linking
telopeptide of type I collagen (CTX), interleukin-6 (IL-6),
vascular endothelial growth factor (VEGF) and transform-
ing growth factor-b.
Results: Patients treated with infliximab showed
significantly greater median increases in BMD of the spine
(2.5%, p,0.001) and hip (0.5%, p=0.033) at week 24
than those who received placebo (0.5% and 0.2%
respectively). Baseline levels of IL-6, VEGF, osteocalcin,
BAP and CTX were significantly correlated with increases
in spinal BMD at weeks 24 and 102 in the infliximab
group. In a multiple regression analysis, high baseline
osteocalcin levels and early increases in BAP at week 2
were significantly associated with increases in BMD
scores of the spine (week 102) and hip (weeks 24 and
102) in the infliximab group.
Conclusions: Patients with AS who received infliximab
showed significant increases in BMD scores over 2 years.
While many significant correlations were observed
between BMD scores of the hip and spine and biomarker
levels, high baseline osteocalcin levels and early increases
in BAP were consistently associated with increases in
BMD scores.
Bone formation and bone resorption, such as
syndesmophytes, ankylosis and erosions, are fea-
tures of progressive ankylosing spondylitis (AS).
However, studies of biochemical markers of bone
turnover in patients with AS have yielded conflict-
ing results. Some studies show normal
12or low
34
levels of bone formation markers, such as osteo-
calcin or bone alkaline phosphatase (BAP), while
other studies show elevated levels of these biomar-
kers.
5 Studies examining markers of bone resorp-
tion (eg, pyridinium cross-linking telopeptide of
type I collagen) in patients with AS also yield
conflicting results.
16 – 9However, elevated levels of
bone resorption markers have been shown to
correlate with inflammatory markers and higher
levels of acute-phase reactants in patients with AS
1
as well as with inflammatory markers in patients
with osteoporosis.
10
In this study, we evaluated changes in the levels
of markers associated with bone turnover and
inflammation in patients with AS who received
infliximab in the Ankylosing Spondylitis Study for
the Evaluation of Recombinant Infliximab
Therapy (ASSERT). We also determined the
relationship between baseline levels and changes
in these markers and increases in bone mineral
density (BMD) after initiation of infliximab
therapy. We hypothesise that changes in these
biochemical markers after treatment with inflix-
imab would be associated with an improvement in
the disease processes corresponding with reduced
inflammation and increased bone growth.
METHODS
Details of the ASSERT study have been previously
published.
11 12 Briefly, patients with AS for at least
3 months before screening were randomly assigned
(3:8) to infusions of placebo or 5 mg/kg infliximab
at weeks 0, 2, 6, 12 and 18. At week 24, patients
assigned to placebo crossed over to 5 mg/kg
infliximab, and both groups continued treatment
every 6 weeks through week 96. Patients originally
assigned to infliximab could receive dose escala-
tions up to 7.5 mg/kg starting at week 36 if their
Bath Ankylosing Spondylitis Disease Activity
Index score was at least 3 for two consecutive
visits.
Sera from patients were collected for biomarker
testing at weeks 0, 2, 24 and 102. BAP (Quidel, San
Diego, California, USA), osteocalcin (Nordic
Biosciences, Herlev, Denmark), and C-terminal
cross-linking telopeptide of type I collagen (CTX)
(Nordic Biosciences) were evaluated as markers of
boneturnover.Interleukin-6(IL-6),vascularendothe-
lial growth factor (VEGF), and transforming growth
factor-b (TGF-b) were evaluated as markers of
inflammation (R&D Systems, Minneapolis, USA).
The BMD of patients aged 20–84 (n=276) was
measured by dual-energy x-ray absorptiometry
(DEXA) evaluations of the hip and spine (L1–L4)
at baseline, week 24 and week 102. Vertebrae
exhibiting abnormalities (eg, fracture or surgical
alteration) were excluded from BMD analysis.
Osteopenia was defined as a T score between
22.5 and 21, exclusive. Osteoporosis was defined
as a T score of 22.5 or lower.
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radiography at baseline and week 102.
13 Briefly, lateral radio-
graphs of the cervical and lumbar spine were scored using the
modified Stoke Ankylosing Spondylitis Spine Score
(mSASSS).
14 15 The anterior sites of the lower and upper portion
of each vertebra were scored from the T12 lower border to the
S1 upper border for the lumbar spine and from the C2 lower
border to the T1 upper border for the cervical spine. Each of the
24 regions was assigned a score of 0 (normal), 1 (erosion,
sclerosis, or squaring), 2 (syndesmophyte) or 3 (bridging
syndesmophyte). Syndesmophytes were defined as regional
scores of 2 or greater. A patient who had a vertebral region score
less than 2 at baseline and greater than or equal to 2 at week 102
was considered to have developed a syndesmophyte.
Statistical analyses
This study is post hoc and exploratory; therefore, the statistics
are descriptive only and are not adjusted for multiplicity.
Changes from baseline to weeks 2 and 24 in biomarker levels
and changes from baseline to week 24 in BMD scores, T scores
and Z scores of the hip and spine were evaluated using an
analysis of variance on the van der Waerden normal scores.
Univariate correlations between individual biomarkers (at
baseline and week 24) and between biomarker levels (at baseline
and per cent change from baseline to weeks 2 and 24) and
changes from baseline to weeks 24 and 102 in spinal and hip
BMD scores were determined using Spearman’s ranking
correlation coefficient. Multiple linear regression analyses were
performed using baseline and change from baseline to week 2 in
biomarker levels (IL-6, VEGF, BAP, osteocalcin and TGF-b),
syndesmophyte development (from baseline to week 102), and
change from baseline to weeks 24 and 102 in BMD scores (hip
and spine) to determine whether serum biomarker levels or
syndesmophyte development were significantly associated with
increases in BMD scores of the spine or hip. Box plots were used
to depict the actual and per cent changes from baseline in BMD
and actual change from baseline in T scores at weeks 24 and
102. Statistical analyses were performed using the SAS system
(SAS Institute, Cary, North Carolina, USA).
RESULTS
Baseline patient characteristics were comparable between
treatment groups (table 1).
Correlations between biomarker levels
Spearman correlation coefficients (r) among biomarker levels at
baseline and week 24 are summarised in table 2.
At baseline, the strongest relationship was observed between
the markers of bone turnover osteocalcin and CTX (r=0.476,
p,0.0001). Significant but modest correlations were observed
between the markers of bone formation BAP and osteocalcin
(r=0.336, p,0.0001) and between BAP and CTX (r=0.367,
p,0.0001). Significant but modest correlations among inflam-
matory markers were observed between IL-6 and VEGF
(r=0.264, p,0.0001) and between VEGF and TGF-b
(r=0.256, p,0.0001).
At week 24 in the infliximab group, the strongest correlations
were observed between IL-6 and VEGF (r=0.446, p,0.0001)
and between VEGF and TGF-b (r=0.494, p,0.0001). Modest
correlations were observed between BAP and osteocalcin
(r=0.391, p,0.0001), IL-6 and osteocalcin (r=20.268,
p,0.005), VEGF and osteocalcin (r=20.288, p,0.005), and
CTX and osteocalcin (r=0.273, p,0.005). In the placebo group
at week 24, significant correlations were observed between
TGF-b and VEGF (r=0.564, p,0.0001), and modest correla-
tions were observed between osteocalcin and CTX (r=0.259,
p,0.05) and between osteocalcin and BAP (r=0.274, p,0.05).
Changes in biomarker levels following infliximab treatment
Percentage changes in biomarker levels from baseline to weeks 2,
24 and 102 are shown in fig 1. A significantly greater median per
cent increase in BAP was observed in the infliximab group at
week 2 (5.8%) compared with the placebo group (20.6%,
p=0.013). The median per cent increase in BAP from baseline
to week 24 in the infliximab group was similar to the value at
week 2 (6.0%), but greater variability was observed in both the
infliximab and placebo groups, and the difference between
groups was not significant (p=0.085). Trends toward a greater
increase in osteocalcin at week 24 (p=0.063) and a greater
reduction in TGF-b at weeks 2 (p=0.059) and 24 (p=0.091)
were observed among patients treated with infliximab. No
differences were observed between the treatment groups in the
changes in CTX levels from baseline to weeks 2 or 24.
After 2 years of therapy, greater median reductions in serum
levels of TGF-b and CTX and greater median increases in BAP
levels were observed as compared with weeks 2 and 24 (fig 1).
Changes in serum marker levels for patients treated with
placebo who crossed over to infliximab at week 24 were similar
to those for patients who were originally assigned to receive
infliximab.
The significant reductions from baseline to weeks 2 and 24 in
serum levels of IL-6 and VEGF observed in patients treated with
infliximab compared with patients treated with placebo in the
ASSERT study have been previously reported.
16
Changes in bone mineral density following infliximab treatment
At week 24, significant increases from baseline in BMD scores
were observed in the spine (p,0.001) and hip (p=0.040) of
patients in the infliximab group (fig 2A). The corresponding
median per cent increase in spinal BMD scores was 2.5% in
patients treated with infliximab and 0.5% in patients treated
with placebo (p,0.001), and the median per cent increase in hip
BMD scores was 0.5% in patients treated with infliximab and
0.2% in patients treated with placebo (p=0.033) (fig 2B).
Similar increases were observed in the T scores of the spine
(p,0.001) and hip (p=0.017) at week 24 (fig 2C). Changes
from baseline to week 102 in spine and hip T scores and total
BMD increased further over the week 24 values for the
infliximab group. The median per cent increase in spinal BMD
scores was 6.8% in the infliximab group and 4.1% in the
placebo/infliximab group; the median per cent increase in hip
BMD scores was 1.8% and 0.9% respectively (fig 2B).
Supplemental table 1 summarises the proportions of patients
with osteopenia or osteoporosis at baseline and weeks 24 and
102.
Syndesmophytes
At baseline, approximately two-thirds of all patients had
syndesmophytes as detected by the analysis of radiographs
(table 1). No statistically significant differences were observed
in the percentage increase in BMD from baseline to week 102 for
patients who developed 1 or more syndesmophytes compared
with those who did not, from baseline to week 102 (supple-
mental table 2).
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Placebo (n=78) 5 mg/kg infliximab (n=201)
Men, no. (%) 68 (87.2%) 157 (78.1%)
Age, years
Mean (SD) 40.3 (9.4) 39.6 (10.6)
Disease duration, years
N 76 201
Mean (SD) 11.9 (8.0) 10.1 (8.7)
Median (range) 13.2 (0.3, 31.6) 7.7 (0.3, 41.1)
HLA-B27 positive
N 78 200
No. (%) 69 (88.5%) 173 (86.5%)
Inflammation (average morning stiffness on a visual
analogue scale 0–10 cm)
N 78 201
Mean (SD) 6.9 (1.9) 6.9 (2.3)
Median (range) 7.0 (0.8, 10.0) 7.3 (0.2, 10.0)
Bone mineral density
Total spine bone mineral density (g/cm
2)
N 73 189
Mean (SD) 1.09 (0.25) 1.01 (0.18)
Median (range) 1.02 (0.77, 2.01) 1.01 (0.63, 1.64)
Spine T scores
N 72 186
Mean (SD) 20.28 (2.00) 20.96 (1.45)
Median (range) 20.75 (22.70, 7.40) 20.95 (24.20, 3.60)
Total hip bone mineral density (g/cm
2)
N 74 192
Mean (SD) 0.95 (0.14) 0.92 (0.14)
Median (range) 0.92 (0.69, 1.36) 0.91 (0.59, 1.38)
Hip T scores
N 74 190
Mean (SD) 20.62 (0.91) 20.75 (0.97)
Median (range) 20.70 (22.20, 2.10) 20.80 (23.30, 2.30)
Hip Z scores
N 74 190
Mean (SD) 20.42 (0.90) 20.54 (0.95)
Median (range) 20.60 (22.00, 2.24) 20.60 (23.00, 2.50)
Syndesmophytes
Patients with syndesmophytes* 54 (71.1%) 122 (61.0%)
Regions with syndesmophytes{ 486 (27.6%) 908 (19.3%)
Biomarker levels
IL-6 (pg/ml)
N 67 187
No. (%) with values >LLOQ 32 (47.8%) 105 (56.1%)
Mean (SD) 11.4 (17.2) 13.2 (20.0)
Median (range) 3.1 (3.1, 119.1) 7.7 (3.1, 174.6)
VEGF (pg/ml)
N 75 193
No. (%) with values >LLOQ 75 (100%) 191 (99.0%)
Mean (SD) 556.2 (385.6) 520.4 (361.5)
Median (range) 473.5 (67.8, 2353.7) 421.5 (29.8, 2067.5)
TGF-b (pg/ml)
N 75 192
No. (%) with values >LLOQ 75 (100%) 192 (100%)
Mean (SD) 45.9 (11.5) 46.8 (11.7)
Median (range) 46.7 (9.4, 85.9) 48.1 (6.0, 90.3)
Osteocalcin (ng/ml)
N 73 197
No. (%) with values >LLOQ 71 (97.3%) 197 (100%)
Mean (SD) 17.4 (8.7) 18.4 (9.9)
Median (range) 15.8 (1.7, 41.3) 16.9 (4.8, 73.5)
BAP (U/l)
N 73 197
No. (%) with values >LLOQ 73 (100%) 197 (100%)
Continued
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mineral density of the spine
Univariate correlations
In the infliximab group, high baseline levels of IL-6 (r=0.146,
p=0.0489), VEGF (r=0.146, p=0.0453), osteocalcin
(r=0.262, p=0.0002), BAP (r=0.262, p=0.0002) and CTX
(r=0.189, p=0.0088) correlated significantly with increases
from baseline to week 24 in spinal BMD scores. Decreases from
baseline to weeks 2 and 24 in IL-6 (r=20.192, p=0.0111 and
r=20.206, p=0.0073 respectively) and VEGF (r=20.245,
p=0.0007 and r=20.226, p=0.0025 respectively) and
increases from baseline to week 24 in BAP (r=0.153,
p=0.0382) also correlated with increases in spinal BMD scores
from baseline to week 24. In the placebo group, no significant
correlations were observed between baseline biomarker levels
and increases in spinal BMD scores at week 24. However,
decreases from baseline to week 2 in IL-6 (r=20.258,
p=0.0392) and increases from baseline to week 24 in CTX
(r=0.241, p=0.0479) correlated with increases in spinal BMD
scores at week 24.
Data for both treatment groups were combined to evaluate
correlations between BMD scores and biomarker levels and
changes from baseline to week 102 because all patients were
receiving infliximab after placebo crossover to infliximab at
week 24. Results for the combined group at week 102 were
similar to week 24. High baseline levels of IL-6 (r=0.207,
p=0.0030), VEGF (r=0.181, p=0.0077), TGF-b (r=0.143,
p=0.0356) and CTX (r=0.179, p=0.0084) correlated mod-
erately with increases in spinal BMD scores at week 102. The
strongest relationships were between the increase in spinal
BMD scores at week 102 and high baseline osteocalcin
(r=0.335, p,0.0001) and BAP (r=0.251, p=0.0002) levels.
Decreases in IL-6 (r=20.255, p=0.0003) and VEGF
(r=20.330, p,0.0001) and increases in BAP (r=0.206,
p=0.0029) at week 2 correlated with increases in spinal
BMD scores at week 102. A similar pattern was observed for
changes at week 24 in the levels of IL-6 (r=20.285,
p,0.0001), VEGF (r=20.280, p,0.0001) and BAP
(r=0.211, p=0.0024). Additionally, there was a weak but
statistically significant correlation between increases in
osteocalcin at week 24 and increases in spinal BMD scores
at week 102 (r=0.168, p=0.0165). Similar changes were
observed when data for only patients with syndesmophytes at
baseline were included in the analysis (data not shown).
Table 1 Continued
Placebo (n=78) 5 mg/kg infliximab (n=201)
Mean (SD) 27.6 (10.1) 26.7 (9.2)
Median (range) 25.4 (8.5, 63.5) 25.0 (10.9, 62.1)
CTX (ng/ml)
N 72 198
No. (%) with values >LLOQ 66 (90.4%) 184 (93.4%)
Mean (SD) 0.39 (0.24) 0.39 (0.25)
Median (range) 0.34 (0.1, 1.6) 0.33 (0.1, 1.8)
BAP, bone alkaline phosphatase; CTX, C-terminal cross-linking telopeptide of type I collagen; HLA, human leucocyte antigen; IL-6,
interleukin-6; LLOQ, lower limit of quantification; TGF-b, transforming growth factor b; VEGF, vascular endothelial growth factor.
*Defined as a patient with at least one vertebral region that received an mSASSS score of >2. See Methods for description of
mSASSS scoring system.
{Defined as any region that received an mSASSS score of >2.
Table 2 Correlations (r) between biomarker values at baseline for all patients and at week 24 for patients in
the infliximab and placebo groups separately
VEGF TGF-b CTX Osteocalcin BAP
Baseline
IL-6 0.264*** 0.105 0.112 0.064 0.040
VEGF 0.256*** 0.052 0.014 0.084
TGF-b 0.034 0.089 0.148*
CTX 0.476*** 0.367***
Osteocalcin 0.336***
Week 24: infliximab
IL-6 0.446*** 0.123 0.035 20.268** 20.157*
VEGF 0.494*** 0.021 20.288** 20.148****
TGF-b 0.074 0.051 0.095
CTX 0.273** 0.169*
Osteocalcin 0.391***
Week 24: placebo
IL-6 20.019 20.041 0.031 20.130 20.114
VEGF 0.564*** 0.102 20.058 0.087
TGF-b 0.162 20.121 0.071
CTX 0.259* 20.062
Osteocalcin 0.274*
BAP, bone alkaline phosphatase; CTX, C-terminal cross-linking telopeptide of type I collagen; IL-6, interleukin-6; TGF-b,
transforming growth factor b; VEGF, vascular endothelial growth factor.
*p,0.05; **p,0.005; ***p,0.0001; ****p=0.0513.
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In the infliximab group, results of a multiple linear regression
analysis using a model including baseline biomarker levels (IL-6,
VEGF, TGF-b, osteocalcin, BAP and CTX), syndesmophyte
development (from baseline to week 102), and changes from
baseline to week 24 in spinal BMD scores revealed that none of
the variables were significantly associated with increases in
spinal BMD scores (table 3). Similarly, per cent changes from
baseline to week 2 in these biomarkers and syndesmophyte
development were not significantly associated with changes
from baseline to week 24 in spinal BMD scores.
Further, in a model that included baseline biomarker levels
(IL-6, VEGF, TGF-b, osteocalcin, BAP, CTX), syndesmophyte
development (from baseline to week 102), and changes in spinal
BMD scores from baseline to week 102, osteocalcin was the only
significant variable associated with increases in spinal BMD
scores. In contrast, the results of a regression analysis using a
model that included changes from baseline to week 2 in
biomarker levels (IL-6, VEGF, TGF-b, osteocalcin, BAP, CTX),
syndesmophyte development (from baseline to week 102), and
changes from baseline to week 102 in spinal BMD scores
revealed that BAP, CTX and VEGF were the only significant
variables associated with increases in spinal BMD scores. None
of the other markers were significantly associated with increases
in spinal BMD scores.
Associations between biomarker levels and changes in bone
mineral density of the hip
Univariate correlations
In the univariate analysis, no baseline biomarker levels
correlated with increases from baseline to week 24 in hip
BMD scores for either treatment group. However, in the
combined group, high baseline levels of TGF-b (r=0.170,
p=0.0140), CTX (r=0.173, p=0.0120), osteocalcin
(r=0.209, p=0.0024) and BAP (r=0.231, p=0.0008) corre-
lated significantly with increases in hip BMD scores from
baseline to week 102.
In the placebo group, there were no significant correlations
between changes in biomarker levels from baseline to weeks 2 or
24 and increases from baseline to week 24 in hip BMD scores. In
the infliximab group, decreases from baseline in VEGF at weeks
2 and 24 (r=20.201, p=0.0061 and r=20.156, p=0.0379
respectively) and increases in BAP from baseline to week 2
(r=0.187, p=0.0111) correlated significantly with increases
from baseline in hip BMD scores at week 24. Similarly, in the
combined group, decreases in VEGF from baseline to weeks 2
and 24 (r=20.187, p=0.0071 and r=20.232, p=0.0010
respectively) and increases from baseline to week 2 in BAP
(r=0.154, p=0.0286) correlated significantly with increases
from baseline to week 102 in hip BMD scores. Also in the
combined group, decreases from baseline to week 24 in IL-6
(r=20.155, p=0.0348) and TGF-b (r=20.173, p=0.0153)
and increases from baseline to week 24 in osteocalcin (r=0.155,
p=0.0295) correlated with increases in hip BMD scores from
baseline to week 102. Similar changes were observed when data
for only patients with syndesmophytes at baseline were
included in the analysis (data not shown).
Multiple regression analyses
In the infliximab group, results of the multiple linear regression
analysis using a model that included baseline biomarker levels
(IL-6, VEGF, TGF-b, osteocalcin, BAP and CTX), syndesmo-
phyte development (from baseline to week 102), and changes
from baseline to week 24 in hip BMD scores revealed that
osteocalcin was the only significant variable associated with
increases in hip BMD scores (table 3). Osteocalcin was also the
only significant variable associated with increases in hip BMD
scores at week 102 using a model that included baseline
biomarker levels (IL-6, VEGF, TGF-b, osteocalcin, BAP, CTX)
and syndesmophyte development (from baseline to week 102).
In contrast, in the infliximab group, the results of a multiple
linear regression analysis using a model that included changes
from baseline to week 2 in serum markers (IL-6, VEGF, TGF-b,
osteocalcin, BAP, CTX), syndesmophyte development (from
baseline to week 102), and changes from baseline to weeks 24
Figure 1 Percentage changes in
biomarker levels at weeks 2, 24 and 102
for transforming growth factor b (A),
osteocalcin (B), bone alkaline
phosphatase (C), and C-terminal cross-
linking telopeptide of type 1 collegen (D).
Boxes indicate medians; error bars
indicate interquartile ranges.
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only significant variables associated with increases in hip BMD
scores at week 24 (table 3). BAP was also significantly associated
with increases in hip BMD scores at week 102. None of the
other markers were significantly associated with increases in hip
BMD scores.
DISCUSSION
To our knowledge, these results represent the largest rando-
mised controlled study of the effect of an antitumour necrosis
factor antibody agent on BMD measurements (spine and hip).
Increases in BMD following treatment with infliximab have been
previously reported for patients with spondyloarthropathy,
17
Figure 2 Actual (A) and per cent (B)
change from baseline in bone mineral
density (BMD) and actual change from
baseline (C) in T scores. Solid horizontal
lines indicate medians, dotted horizontal
lines indicate means, boxes indicate
interquartile ranges, and error bars
indicate standard deviations.
Extended report
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18 19 and Crohn’s disease.
20 In our study,
greater increases in both spine and hip BMD scores were observed
at week 24 in patients who received infliximab compared with
placebo. The differences between the groups were greater for the
spine than for the hip. Placebo-treated patients who crossed over
to infliximab at week 24 showed increases in BMD scores at week
102; however, the magnitude of increase in BMD for patients
initially assignedtoinfliximabtreatment was greater atweek102,
suggesting a benefit from earlier treatment with infliximab.
In the current study, treatment with infliximab resulted in
stronger correlations between IL-6 and VEGF and between
VEGF and TGF-b but weaker correlations between CTX and
osteocalcin and between CTX and BAP. These results suggest
that changes in levels of IL-6, VEGF and TGF-b are associated
with the changes in disease processes that occur with infliximab
treatment in AS. Significant univariate correlations were
observed between baseline osteocalcin and both increases in
spinal BMD scores at weeks 24 and 102 and increases in hip
BMD scores at week 102 in the infliximab group. Further, in the
multiple regression analysis that included all biomarkers and
syndesmophyte development, only baseline osteocalcin levels
were consistently associated with increases in spinal and hip
BMD scores at week 102 for patients in the infliximab group.
Baseline osteocalcin levels were also associated with increases in
BMD hip scores at week 24. In comparison, two small-scale
studies lacking follow-up of treatment effects in patients with
AS did not show a relationship between osteocalcin levels and
BMD scores.
21 22 Our results suggest that baseline osteocalcin
levels may have utility for predicting increases in hip and spinal
BMD scores among patients with AS receiving infliximab.
Infliximab treatment significantly increased the levels of the
bone formation marker BAP; although, the magnitude of
median increases from baseline at weeks 2 and 24 were small
(approximately 6%), with wide variability among patients
within each treatment group. Greater increases from baseline
in BAP were observed at week 102 (33–38%), but these changes
cannot be specifically attributed to infliximab because the study
was not placebo-controlled after week 24. Further, significant
univariate correlations were observed in the infliximab group
between baseline BAP and both increases in spinal BMD scores
at weeks 24 and 102 and increases in hip BMD scores at week
102. The results of a multiple regression analysis showed that
early increases from baseline to week 2 in BAP were significantly
associated with increases in BMD hip scores at week 24 and
increases in both spinal and hip BMD scores at week 102 in the
infliximab group.
Treatment with infliximab in patients with Crohn’s disease
has been previously shown to result in a significant increase in
BAP but not in N-telopeptide of type I collagen, a marker of
bone resorption.
23 The increases in BAP might be a result of
tumour necrosis factor-a inhibition and the steroid-sparing
effect of infliximab in Crohn’s disease. However, this explana-
tion is not applicable to our analysis given that patients were
prohibited from corticosteroid use in ASSERT. In contrast, a
study of patients with rheumatoid arthritis treated with
infliximab showed a significant decrease in N telopeptide of
type I collagen levels without an associated increase in BAP
levels after treatment,
24 supporting a disconnect between these
markers of bone formation and resorption. These results suggest
that BAP may be a good marker of early changes in spine and
hip BMD scores in response to treatment with infliximab.
We have shown previously that treatment with infliximab
results in significant, early decreases in the inflammatory
markers IL-6 and VEGF in patients with AS as compared with
placebo.
16 In our study, early median decreases in TGF-b were
greater in the infliximab group than in the placebo group, but
this difference was not statistically significant. Significant
univariate correlations in the infliximab group were observed
between early decreases in IL-6 and VEGF levels and increases in
spinal BMD scores at weeks 24 and 102, and early decreases in
VEGF were also associated with increases in hip BMD scores at
weeks 24 and 102. Additionally, baseline VEGF levels correlated
Table 3 Associations between biomarker levels and the change from baseline to weeks 24 and 102 in bone
mineral density for patients in the infliximab group
Model r
2 b* p Value
Spine BMD: % change from baseline to week 24
Baseline biomarker levels, n=144 NS NS NS
% change from baseline to week 2 in biomarker levels, n=135 NS NS NS
Spine BMD: % change from baseline to week 102
Baseline biomarker levels, n=141 0.111
Osteocalcin 0.254 0.019
% change from baseline to week 2 in biomarker levels, n=132 0.174
BAP 0.138 0.003
CTX 20.035 0.024
VEGF 20.081 0.046
Hip BMD: % change from baseline to week 24
Baseline biomarker levels, n=143 0.153
Osteocalcin 0.084 0.002
% change from baseline to week 2 in biomarker levels, n=135 0.121
BAP 0.027 0.019
CTX 20.008 0.038
Hip BMD: % change from baseline to week 102
Baseline biomarker levels, n=141 0.237
Osteocalcin 0.172 ,0.0001
% change from baseline to week 2 in biomarker levels, n=133 0.111
BAP 0.038 0.039
BAP, bone alkaline phosphatase; BMD, bone mineral density; CTX, C-terminal cross-linking telopeptide of type I collagen; NS, not
significant; VEGF, vascular endothelial growth factor.
*Represents the intercept value in the linear regression equation (y=mx+b).
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Ann Rheum Dis 2009;68:175–182. doi:10.1136/ard.2007.084426 181significantly with increases in spinal BMD scores from baseline
to weeks 24 and 102, and baseline TGF-b levels correlated
significantly with increases in hip BMD scores from baseline to
week 102.
Increases in BMD scores in patients with AS may be
confounded by the formation of syndesmophytes. However,
in this study, patients who developed syndesmophytes had
similar changes in BMD as those who did not develop
syndesmophytes. Further, syndesmophyte development was
not a significant variable associated with changes in either hip
or spinal BMD scores at week 24 or 102 in our multiple
regression models. Thus, the increases in BMD scores observed
in patients treated with infliximab do not appear to be linked to
syndesmophyte development in this study.
There are several important limitations to this study. This
secondary analysis from the ASSERT study was not powered to
assess the significance of relationships between changes in
biomarker levels and the BMD of patients with AS who received
infliximab. Changes in BMD were only assessed at two time
points (weeks 24 and 102), and changes in biomarker levels were
only assessed at three time points (weeks 2, 24 and 102);
fluctuations of these variables between time points were not
studied. A more frequent, and perhaps longer, follow-up of
patients would provide a more complete understanding of the
long-term effects of infliximab therapy on both fluctuations in
biomarker levels and BMD of the spine and hip in patients with
AS. The variability in the changes in biomarker levels,
particularly at weeks 2 and 24, limits the utility of these
surrogate markers of BMD at the individual patient level.
In conclusion, patients with AS who received infliximab
showed significant increases in BMD of the hip and spine at
24 weeks and 2 years. High baseline osteocalcin levels and early
increases in BAP were consistently associated with these
increases in BMD.
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